Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
8
×
indiana blog main
indiana top stories
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
8
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
life sciences
clinical trials
biotech
startups
abbvie
abeona therapeutics
affordable care act
alzheimer's
cancer
cancer immunotherapy
crispr
deals
eli lilly
What
roundup
8
×
bio
american
continue
people
ahead
based
best
cancer
congress
crash
days
debate
healthcare
industry
kind
month
nash
pharma
pharmaceutical
policy
politicians
pressure
scalps
trump’s
u.s
abbvie’s
acquisitions
alzheimer’s
ambien
announced
annual
asco
attendees
attention
biofourmis
biopharma
biotech
black
bucks
Language
unset
Current search:
sanofi
×
roundup
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More